Botulinum toxin type A

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children

Conditions

Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children

Trial Timeline

Apr 1, 2014 → Sep 4, 2018

NCT ID

NCT02106351

About Botulinum toxin type A

Botulinum toxin type A is a phase 3 stage product being developed by Ipsen for Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children. The current trial status is completed. This product is registered under clinical trial identifier NCT02106351. Target conditions include Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03017729	Pre-clinical	Completed	Feb 10, 2017	Nov 30, 2020	Lower Limb Spasticity
NCT02969356	Approved	Completed	Dec 18, 2016	Jul 1, 2018	Spastic Hemiparesis
NCT02020980	Pre-clinical	Completed	Apr 1, 2014	Mar 5, 2018	Lower Limb Spasticity
NCT02106351	Phase 3	Completed	Apr 1, 2014	Sep 4, 2018	Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
NCT01753336	Phase 3	Completed	Mar 1, 2013	Oct 1, 2015	Cervical Dystonia
NCT01753349	Pre-clinical	Completed	Dec 1, 2012	Sep 25, 2017	Cervical Dystonia
NCT01682148	Phase 3	Terminated	Sep 1, 2012	Mar 1, 2015	Arm Spasticity
NCT01313312	Phase 3	Completed	Nov 1, 2011	Dec 1, 2014	Nervous System Disorders
NCT01251380	Phase 3	Completed	Oct 1, 2011	Jan 1, 2015	Cerebral Palsy
NCT01251367	Phase 3	Completed	Jun 1, 2011	Apr 1, 2015	Post-stroke Spasticity
NCT00455637	Phase 2	Terminated	Mar 1, 2007	Mar 17, 2008	Cerebral Palsy
NCT00288509	Phase 3	Completed	Feb 1, 2006	Jan 1, 2008	Cervical Dystonia
NCT00276315	Phase 3	Completed	Dec 1, 2005	Jan 1, 2007	Hemifacial Spasm
NCT00246142	Phase 3	Completed	Apr 1, 2005	Jun 27, 2007	Myofascial Pain Syndromes
NCT00134810	Phase 2	Completed	Mar 1, 2005	May 18, 2006	Myofascial Pain Syndromes
NCT00149240	Phase 2	Completed	Jan 1, 2005	Feb 2, 2006	Myofascial Pain Syndromes
NCT00246155	Phase 3	Completed	Jan 1, 2005	Jul 1, 2005	Low Back Pain
NCT00447772	Phase 3	Completed	Oct 1, 2004	Apr 1, 2008	Cervical Dystonia
NCT00247559	Phase 2	Completed	May 1, 2004	Apr 8, 2005	Lateral Canthal Lines
NCT00210444	Phase 2	Completed	Jun 1, 2003	Dec 1, 2006	Anal Fissure

Competing Products

20 competing products in Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children

See all competitors

Product	Company	Stage	Hype Score
Nivolumab 100 MG in 10 ML Injection	Ono Pharmaceutical	Phase 2	52
Remimazolam Tosilate	Jiangsu Hengrui Medicine	Approved	85
ABBV-950 + BOTOX + Placebo for ABBV-950	AbbVie	Phase 1	33
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	52
BOTOX	AbbVie	Approved	85
MK-3475 and BCG	Merck	Phase 2	52
Montelukast + Placebo	Merck	Approved	85
Muntelukast + Placebo	Merck	Phase 3	77
IFF flavor 316 282, Paracetamol, Pseudoephedrine	Novartis	Phase 3	77
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets	Novartis	Phase 3	77
diclofenac potassium + nimesulide	Novartis	Approved	85
Diclofenac gel	Novartis	Approved	85
IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin	Novartis	Phase 3	77
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab	Gilead Sciences	Phase 3	76
Azithromycin SR	Pfizer	Phase 3	76
Nivolumab	Bristol Myers Squibb	Pre-clinical	22
Nivolumab	Bristol Myers Squibb	Pre-clinical	22
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)	Regeneron Pharmaceuticals	Phase 2	51
IPN10200 + IPN10200 Placebo + Dysport	Ipsen	Phase 1/2	38
AboBoNT-A + OnaBoNT-A	Ipsen	Approved	82

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved

lanreotide acetateApproved

Tigan® + PlaceboApproved

Diosmectite (Smecta®)Approved

lanreotide (Autogel formulation)Approved